CYP17 polymorphism and tamoxifen-induced hepatic steatosis

Hepatology Research

Volumn 33, Issue 2, 2005, Pages 178-180

  Ohnishi, Takenao ^a   Ogawa, Yasuhiro ^a   Saibara, Toshiji ^a   Nishioka, Akihito ^a   Kariya, Shinji ^a   Fukumoto, Mitsutaka ^a   Onishi, Saburo ^a   Yoshida, Shoji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; CYP17; Estrogen; Hepatic steatosis; Nonalcoholic steatohepatitis; Polymorphism; Tamoxifen

Indexed keywords

CYTOCHROME P450 17; GENOMIC DNA; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISEASE COURSE; DNA DETERMINATION; FATTY LIVER; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

EID: 29144466581     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.09.030     Document Type: Article

References (16)

1. N.R. Wilcken Tamoxifen hits the target in situ Lancet 353 1999 1986-1987
2. Y. Ogawa Y. Murata A. Nishioka T. Inomata S. Yoshida Tamoxifen-induced fatty liver in patients with breast cancer Lancet 351 1998 725
3. T. Saibara S. Onishi Y. Ogawa S. Yoshida H. Enzan Non-alcoholic steatohepatitis Lancet 354 1999 1299-1300
4. Farrell GC Drugs and steatohepatitis Semin Liver Dis 22 2002 185-194
5. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221-1231
6. K.S. Kumar P.F. Malet Nonalcoholic steatohepatitis Mayo Clin Proc 75 2000 733-739
7. Y. Falck-Ytter Z.M. Younossi G. Marchesini A.J. McCullough Clinical features and natural history of nonalcoholic steatosis syndromes Semin Liver Dis 21 2001 17-26
8. Y. Murata Y. Ogawa T. Saibara et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients Oncol Rep 7 2000 1299-1304
9. M. Nishino K. Hayakawa Y. Nakamura T. Morimoto S. Mukaihara Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: High frequency of involvement and rapid reversal after completion of tamoxifen therapy AJR Am J Roentgenol 180 2003 129-134
10. Y. Nemoto K. Toda M. Ono et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice J Clin Invest 105 2000 1819-1825
11. M.E. Jones A.W. Thorburn K.L. Britt et al. Aromatase-deficient (ArKO) mice accumulate excess adipose tissue J Steroid Biochem Mol Biol 79 2001 3-9
12. A.H. Carey D. Waterworth K. Patel et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17 Hum Mol Genet 3 1994 1873-1876
13. T. Habuchi Z. Liqing T. Suzuki et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect Cancer Res 60 2000 5710-5713
14. B.E. Feigelson L.S. Shames M.C. Pike et al. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations Cancer Res 58 1998 585-587
15. C.A. Haiman S.E. Hankinson D. Spiegelman et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer Cancer Res 59 1999 1015-1020
16. C.A. Haiman S.E. Hankinson G.A. Colditz D.J. Hunter I. De Vivo A polymorphism in CYP17 and endometrial cancer risk Cancer Res 61 2001 3955-3960